iTonic Holdings Ltd Class A Ordinary Shares (ITOC)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses I can understand, with durable advantages and honest numbers. iTonic is a seven-employee healthcare company selling brachytherapy treatment-planning software and devices. That is a narrow, specialized niche, and the supplied figures show no evidence of a moat: no revenue growth data, no profit growth data, and only zero years of filed results, so the Lynch screen gives it no category. As of the 2026-10-13 close, the stock was $3.94, giving a $5.0M market cap. FairStock's calculations show a negative P/E of -12.31, a price-to-book of 10.94, ROE of -71.25%, and ROCE of -40.98%. Those are not the marks of a compounding machine; they say the company is losing money and the price is rich relative to book value. The balance sheet has low leverage—D/E 0.02—which is a modest positive, but the Piotroski F-Score is only 2/9 and the Altman Z-Score is 2.73, a gray-zone reading at best. Beta of 2.77 and a 52-week range of $0.22 to $4.64 warn that this is a highly volatile microcap. Without multi-year filed financials, I cannot judge growth or consistency. Mr. Market may be pricing hope, not proven earning power. I would need a much larger margin of safety and a long record of cash generation before calling this investment-grade.

In plain English: iTonic Holdings makes software and devices used in a cancer treatment called brachytherapy. It is a very small company with only seven employees, and the numbers show losses, weak returns, and a stock price that looks high compared with its book value. Based on the figures given, the business does not look strong and the price does not look cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer